Prevention Strategies for Cytomegalovirus Disease and Long-Term Outcomes in the High-Risk Transplant Patient (D+/R-): Experience from the RESITRA-REIPI Cohort

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.endPage396
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue3
UDC.journalTitleTransplant Infectious Disease
UDC.startPage387
UDC.volume16
dc.contributor.authorMeije, Yolanda
dc.contributor.authorFortún, Jesús
dc.contributor.authorLen, Óscar
dc.contributor.authorAguado, José María
dc.contributor.authorMoreno, Asunción V.
dc.contributor.authorCisneros, José Miguel
dc.contributor.authorGurgui, Mercé
dc.contributor.authorCarratalá, Jordi A.
dc.contributor.authorMuñoz-García, Patricia E.
dc.contributor.authorMontejo, Miguel
dc.contributor.authorBlanes, Marino
dc.contributor.authorBou, Germán
dc.contributor.authorBeato Pérez, José Luis
dc.contributor.authorTorre-Cisneros, Julián
dc.contributor.authorRamos-Martínez, Antonio S.D.
dc.contributor.authorPahissa, Alberto
dc.contributor.authorGavaldá, Joan
dc.date.accessioned2026-10-28T07:27:35Z
dc.date.available2026-10-28T07:27:35Z
dc.date.issued2014-05-08
dc.descriptionMulticenter study
dc.description.abstract[Abstract] Background: Cytomegalovirus (CMV)-negative recipients of a graft from a CMV-positive donor (D+/R-) are at high risk of CMV disease. Current preventive strategies include universal prophylaxis (UP) and preemptive therapy (PT). However, the best strategy to prevent CMV disease and achieve better long-term outcomes remains a matter of debate. Methods: We analyzed the incidence of CMV disease and long-term outcomes including graft dysfunction and patient mortality at 5 years after transplantation with both preventive strategies. High-risk (D+/R-) kidney and liver transplant recipients from the RESITRA cohort were included. Results: Of 2410 kidney or liver transplant patients, 195 (8.3%) were D+/R-. The final cohort included 58 liver and 102 kidney recipients. UP was given in 92 patients and 68 received PT; 10.9% and 36.8% developed CMV disease, respectively (P < 0.01). The independent risk factors for CMV disease were PT strategy (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.6-6.9), kidney transplantation (HR, 3.8; 95% CI, 1.4-9.9), and cyclosporine immunosuppression (HR, 2.4; 95% CI, 1.2-4.7). PT strategy was also a risk factor for CMV disease in both liver transplantation (HR, 11.0; 95% CI, 1.2-98.7) and kidney transplantation (HR, 2.7; 95% CI, 1.3-6.0), independently. The development of CMV replication during the first 2 years after transplantation was a risk factor for graft dysfunction at 5 years after transplantation (odds ratio, 3.4; 95% CI, 1.3-9.0). Nevertheless, no significant differences were seen in either graft dysfunction or mortality between the 2 strategies. Conclusions: The study supports the benefit of the UP strategy to prevent CMV disease in D+/R- liver or kidney transplant patients. The development of CMV replication during the first 2 years after transplantation was associated with graft dysfunction at 5 years after transplantation.
dc.description.sponsorshipThis manuscript was supported by the Spanish Ministry of Health and Consumer Affairs, Instituto de Salud Carlos III, Spanish Network for research on Infection in Transplantation (grant G03/075), and Spanish Network for Research on Infectious Diseases (grant RD06/0008). Dr Y. Meije held a “Río Hortega” grant from ISCIII (Instituto de Salud Carlos III) and Fundación Hospital Ramón y Cajal.
dc.identifier.citationMeije Y, Fortún J, Len Ó, Aguado JM, Moreno A, Cisneros JM, Gurguí M, Carratalà J, Muñoz P, Montejo M, Blanes M, Bou G, Pérez JL, Torre-Cisneros J, Ramos A, Pahissa A, Gavaldà J; Spanish Network for Research on Infection in Transplantation (RESITRA) and the Spanish Network for Research on Infectious Diseases (REIPI). Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis. 2014 Jun;16(3):387-96.
dc.identifier.doi10.1111/TID.12226
dc.identifier.issn1399-3062
dc.identifier.urihttps://hdl.handle.net/2183/50005
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.projectIDinfo:eu-repo/grantAgreement/MSC//RD06%2F0008%2F1019/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍA INFECCIOSA (REIPI)/
dc.relation.urihttps://doi.org/10.1111/TID.12226
dc.rightsThis is the peer reviewed version of the article which has been published in final form at Transplant Infectious Disease. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
dc.rights.accessRightsopen access
dc.subjectD+/R−
dc.subjectCytomegalovirus
dc.subjectGraft dysfunction
dc.subjectPreemptive therapy
dc.subjectTransplantation
dc.subjectUniversal prophylaxis
dc.titlePrevention Strategies for Cytomegalovirus Disease and Long-Term Outcomes in the High-Risk Transplant Patient (D+/R-): Experience from the RESITRA-REIPI Cohort
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Meije_Prevention_2014.pdf
Size:
365.82 KB
Format:
Adobe Portable Document Format